Effect of clarithromycin on experimental rhinovirus-16 colds: A randomized, double-blind, controlled trial

American Journal of Medicine

Volumn 108, Issue 6, 2000, Pages 453-459

  Abisheganaden, John A ^a   Avila, Pedro C ^a   Kishiyama, Jeffrey L ^a   Liu, Jane ^b   Yagi, Shigeo ^c   Schnurr, David ^c   Boushey, Homer A ^a,b  

^a Division of Allergy/Immunology   (United States)

^b Division of Pulmonary and Critical Care Medicine   (United States)

^c VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; COTRIMOXAZOLE; CYTOKINE; INTERLEUKIN 6; MACROLIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; FEMALE; HUMAN; MALE; MUCUS SECRETION; NOSE AIRFLOW; NOSE SECRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOVIRUS;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CLARITHROMYCIN; COMMON COLD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTE COUNT; MALE; NASAL LAVAGE FLUID; NEUTROPHILS; PROSPECTIVE STUDIES; RHINOVIRUS; SEVERITY OF ILLNESS INDEX; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0034655178     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00329-6     Document Type: Article

References (39)

1. McCaig L.F., Hughes J.M. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 273:1995;214-219.
2. Hendley J.O. Rhinovirus colds immunology and pathogenesis . Eur J Respir Dis. 128:(suppl pt 1):1983;340-344.
3. Gwaltney J.M. Jr, Hendley J.O., Simon G., Jordan W.S. Jr. Rhinovirus infections in an industrial population. 3. Number and prevalence of serotypes. Am J Epidemiol. 87:1968;158-166.
4. Nyquist A.C., Gonzales R., Steiner J.F., Sande M.A. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA. 279:1998;875-877.
5. Mainous A.G. 3rd, Hueston W.J., Clark J.R. Antibiotics and upper respiratory infection do some folks think there is a cure for the common cold? J Fam Pract. 42:1996;357-361.
6. Wise R. Antibiotics for the uncommon cold. Lancet. 347:1996;1499.
7. Seppala H., Nissinen A., Jarvinen H., et al. Resistance to erythromycin in group A streptococci. NEJM. 326:1992;292-297.
8. Black P.N. Anti-inflammatory effects of macrolide antibiotics. Eur Respir J. 10:1997;971-972.
9. Labro M.T. Anti-inflammatory activity of macrolides a new therapeutic potential? J Antimicrob Chemother. 41:(suppl B):1998;37-46.
10. Tamaoki J., Takeyama K., Tagaya E., Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother. 39:1995;1688-1690.
11. Rubin B.K., Druce H., Ramirez O.E., Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med. 155:1997;2018-2023.
12. Hendley J.O. The host response, not the virus, causes the symptoms of the common cold. Clin Infect Dis. 26:1998;847-848.
13. Folkerts G., Busse W.W., Nijkamp F.P., et al. Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med. 157:1998;1708-1720.
14. Fraenkel D.J., Bardin P.G., Sanderson G., et al. Immunohistochemical analysis of nasal biopsies during rhinovirus experimental colds. Am J Respir Crit Care Med. 150:1994;1130-1136.
15. Yuta A., Doyle W.J., Gaumond E., et al. Rhinovirus infection induces mucus hypersecretion. Am J Physiol. 274:1998;L1017-L1023.
16. Fleming H.E., Little F.F., Schnurr D., et al. Rhinovirus-16 colds in healthy, and asthmatic subjects. Similar changes in upper and lower airways. Am J Respir Crit Care Med. 160:1999;100-108.
17. Teran L.M., Johnston S.L., Schroder J.M., et al. Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma. Am J Respir Crit Care Med. 155:1997;1362-1366.
18. Grunberg K., Timmers M.C., Smits H.H., et al. Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin Exp Allergy. 27:1997;36-45.
19. Corne J.M., Holgate S.T. Mechanisms of virus induced exacerbations of asthma. Thorax. 52:1997;380-389.
20. Takizawa H., Desaki M., Ohtoshi T., et al. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells a potential mechanism of its anti-inflammatory action . Biochem Biophys Res Commun. 210:1995;781-786.
21. Takizawa H., Desaki M., Ohtoshi T., et al. Erythromycin modulates IL-8 expression in normal, and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med. 156:1997;266-271.
22. Tamaoki J., Sakai N., Tagaya E., Konno K. Macrolide antibiotics protect against endotoxin-induced vascular leakage and neutrophil accumulation in rat trachea. Antimicrob Agents Chemother. 38:1994;1641-1643.
23. Oishi K., Sonoda F., Kobayashi S., et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun. 62:1994;4145-4152.
24. Tamaoki J., Tagaya E., Yamawaki I., et al. Effect of erythromycin on endotoxin-induced microvascular leakage in the rat trachea and lungs. Am J Respir Crit Care Med. 151:1995;1582-1588.
25. Goswami S.K., Kivity S., Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis. 141:1990;72-78.
26. Labro M.T. Immunomodulation by antibacterial agents. Is it clinically relevant? Drugs. 45:1993;319-328.
27. Jackson G.G., Dowling H.F., Spiesman I.G., Boand A.V. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. Arch Intern Med. 101:1958;267-278.
28. Gwaltney J.M. Jr, Hendley O., Hayden F.G., et al. Updated recommendations for safety-testing of viral inocula used in volunteer experiments on rhinovirus colds. Prog Med Virol. 39:1992;256-263.
29. Knight V. The use of volunteers in medical virology. Prog Med Virol. 6:1964;1-26.
30. Roche Y., Gougerot-Pocidalo M.A., Fay M., et al. Macrolides and immunity effects of erythromycin and spiramycin on human mononuclear cell proliferation . J Antimicrob Chemother. 17:1986;195-203.
31. Labro M.T., el Benna J., Babin-Chevaye C. Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother. 24:1989;561-572.
32. Kudoh S., Uetake T., Hagiwara K., et al. Clinical effect of low-dose, long-term erythromycin chemotherapy on diffuse panbronchiolitis. Jpn J Thor Dis. 25:1987;632-643.
33. Kadota J., Sakito O., Kohno S., et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 147:1993;153-159.
34. Yamamoto M., Kondo A., Tamura A., et al. Long-term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis. Jpn J Thor Dis. 28:1990;1305-1313.
35. Nagani H., Shishido H., Yoneda R., et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration. 58:1991;145-149.
36. Miyatake H., Taki F., Taniguchi H., et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest. 99:1991;670-673.
37. Koh Y.Y., Lee M.H., Sun Y.H., et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis a double-blind, placebo-controlled study . Eur Respir J. 10:1997;994-999.
38. Jaffe A., Francis J., Rosenthal M., Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 351:1998;420.
39. Kaiser L., Lew D., Hirschel B., et al. Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet. 347:1996;1507-1510.